Impact of pre-transplant anaemia correction and erythropoietin resistance on long-term graft survival

Nephrology Dialysis Transplantation

Volumn 20, Issue SUPPL. 8, 2005, Pages

  Campise, Mariarosaria ^a   Mikhail, Ashraf ^b   Quaschning, Thomas ^c   Snyder, Jon ^d   Collins, Allan ^d  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b MORRISTON HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Aggressive treatment; Anaemia; Graft failure; Patient survival; Post transplant patients; rHuEPO hyporesponsiveness

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HEMODIALYSIS; HUMAN; INCIDENCE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERITONEAL DIALYSIS; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; REOPERATION; TIME; TREATMENT OUTCOME; AGED; DRUG RESISTANCE; MIDDLE AGED;

ADULT; AGED; ANEMIA; DRUG RESISTANCE; ERYTHROPOIETIN, RECOMBINANT; FEMALE; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 27144484634     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfh1110     Document Type: Article

References (23)

1. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease. Circulation 2003; 108: 2154-2169
2. Kasiske BL. Epidemiology of cardiovascular disease after renal transplantation. Transplantation 2001; 72: S5
3. Varma R, Garrick R, McClung J et al. Chronic renal dysfunction as an independent risk factor for the development of cardiovascular disease. Cardiol Rev 2005; 13: 98-107
4. Kadambi PV, Javaid B. Cardiovascular disease in kidney transplant recipients: The role of anemia. Adv Chronic Kidney Dis 2004; 11: 328-333
5. Pereira AA, Sarnak MJ. Anemia as a risk factor for cardiovascular disease. Kidney Int 2003; 87: S32-S39
6. Drueke T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 2001; 16 [Suppl 7]: 25-28
7. Macdougall IC, Cooper A. The inflammatory response and epoietin sensitivity. Nephrol Dial Transplant 2001; 17 [Suppl 1]: 48-52
8. Sadeghi M, Daniel V, Weimer R et al. Differential early posttransplant cytokine responses in living and cadaver donor renal allografts. Transplantation 2003; 75: 1351-1355
9. Lietz K, Lao M, Paczek L et al. The impact of pretransplant erythropoietin therapy on late outcomes of renal transplantation. Ann Transplant 2003; 8: 17-24
10. Locatelli F, Aljama P, Barany P et al. European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 [Suppl 2]: Ii1-ii47
11. Vanrenterghem Y, Ponticelli C, Morales JM et al. Prevalence and management of anemia in renal transplant recipients: A European Survey. Am J Transplant 2003; 3: 835-845
12. Sarnak MJ, Tighiouart H, Manjunath G et al. Anemia as a risk factor for cardiovascular disease in the Atherosclerosis Risk Communities (AIRC) study. J Am Coll Cardiol 2002; 40: 27-33
13. Foley RN, Parfrey PS, Harnett JD et al. The impact of anaemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28: 53-61
14. Levin A. Anaemia and left ventricular hypertrophy in chronic kidney disease populations: A review of the current state of knowledge. Kidney Int 2002; 64: S35-S38
15. Rigatto C, Parfrey P, Foley R et al. Congestive heart failure in renal transplant recipients: Risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol 2002; 13: 1084-1090
16. Muirhead N. Erythropoietin and renal transplantation. Kidney Int 1999; 55: S86-S92
17. Becker BN, Becker YT, Leverson GE, Heisey DM. Erythropoietin therapy may retard progression in chronic renal transplant dysfunction. Nephrol Dial Transplant 2002; 17: 1667-1673
18. Wheeler DC, Steiger J. Evolution and etiology of cardiovascular disease in renal transplant recipients. Transplantation 2000; 70: S41-S45
19. Stenvinkel P. The role of inflammation in the anaemia of end-stage renal disease. Nephrol Dial Transplant 2001; 16 [Suppl 7]: 36-40
20. Hirayama A, Nagase S, Gotoh M et al. Reduced serum hydroxyl radical scavenging activity in erythropoietin therapy resistant renal anemia. Free Radic Res 2002; 36: 1155-1161
21. Campise M, Bamonti F, Novembrino C et al. Oxidative stress in kidney transplant patients. Transplantation 2003; 75 [10]: 1474-1478
22. Montagnino G, Tarantino A, Cesana B et al. Prognostic factors of long-term allograft survival in 632 CyA-treated recipients of a primary renal transplant. Transpl Int 1997; 10: 268-275
23. Knoll GA, MacDonald I, Kahan A et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003; 14: 2381-2386